DZD

AM Best Affirms Credit Ratings of Compagnie Algérienne des Assurances

Retrieved on: 
Thursday, November 9, 2023
Insurance, Professional Services, CAAT, Risk management, Credit, GWP, DZD, AM Best, News, ALL

AM Best has affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of “bb+” (Fair) of Compagnie Algérienne des Assurances (CAAT) (Algeria).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of “bb+” (Fair) of Compagnie Algérienne des Assurances (CAAT) (Algeria).
  • The outlook of these Credit Ratings (ratings) is stable.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics

Retrieved on: 
Tuesday, November 14, 2023
World Health Organization, ID, Research, ONT, WHO, Risk, Oxford Nanopore Technologies, Mortality, Sepsis, Patient, Death, FDA, DZD, Workflow, Diagnosis, Infection, Blood culture, Nanopore sequencing, Day Zero, Health, Hospital, Collaboration, Bloodstream infections, Vaccine, Medical device, Fine chemical

According to the World Health Organization (WHO), there are 11 million sepsis-related deaths every year, accounting for one in five deaths worldwide.

Key Points: 
  • According to the World Health Organization (WHO), there are 11 million sepsis-related deaths every year, accounting for one in five deaths worldwide.
  • Early and effective treatment is paramount in a severe infection because the risk of mortality can increase by the hour.
  • "We are pleased to launch this collaboration with Oxford Nanopore that integrates nanopore sequencing innovations with Day Zero Diagnostics' platform technologies to develop a first-of-its kind diagnostic solution for sepsis," said Jong Lee, CEO and co-founder of Day Zero Diagnostics.
  • "We are excited to partner with Day Zero Diagnostics to bring the benefits of nanopore sequencing to fight bloodstream infections," said Gordon Sanghera, CEO of Oxford Nanopore Technologies.

Day Zero Diagnostics Names Jeff Mirviss Chair of Board of Directors

Retrieved on: 
Tuesday, October 24, 2023
Government, AdvaMed, State Government Affairs Council, Infection, Health, Central Executive Committee of the Pakistan Peoples Party, Marketing, Executive Committee, DZD, Independent Board for Presbyterian Foreign Missions, Management, Boston Scientific

BOSTON, Oct. 24, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today that independent board member, Jeff Mirviss, has been appointed board chair.

Key Points: 
  • BOSTON, Oct. 24, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today that independent board member, Jeff Mirviss, has been appointed board chair.
  • "Jeff has been an important advisor, investor and supporter of DZD since the early days of our company and the company has benefitted greatly from his involvement and counsel," said Jong Lee, CEO and co-founder, Day Zero Diagnostics.
  • Outside of Boston Scientific, Mr. Mirviss serves on the Executive Board of AdvaMed, the industry association for medtech and diagnostic companies.
  • "I'm honored to be elected chair of the Day Zero Diagnostics Board of Directors and look forward to continuing to work with my colleagues on the Board, as well as the visionary team at DZD," said Jeff Mirviss, chair, DZD Board of Directors.

Day Zero Diagnostics to Present AI-Based Antimicrobial Susceptibility Testing Predictive Models at ID Week

Retrieved on: 
Tuesday, October 10, 2023
ID, DZD, AST, HAI, Infection, Infectious Diseases Society of America, WGS, ABC, Computational biology, Television, Vaccine

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today that it has been selected to deliver two presentations at the 2023 ID Week conference. ID Week is the premier annual conference organized by the Infectious Disease Society of America and will take place October 11-15 in Boston.

Key Points: 
  • ID Week is the premier annual conference organized by the Infectious Disease Society of America and will take place October 11-15 in Boston.
  • Dr. Miriam Huntley, Chief Technology Officer, will present Keynome® gAST, Day Zero Diagnostics' AI-based algorithm that uses whole genome sequences to predict the antimicrobial susceptibility (AST) of an infection, and discuss how this novel technology will impact the future diagnostics and treatment of infectious disease.
  • In addition to the scientific talks, Day Zero Diagnostics is launching a new commercial service at ID Week under its Day Zero Lab Services brand.
  • This new service expands Day Zero Lab Services commercial offerings and is a complement to epiXact® HAI – DZD's market-leading CLIA-certified healthcare-associated infection (HAI) outbreak assay.

Day Zero Diagnostics Welcomes Microbiology and Genomic Researcher Dr. Patricia Simner to Advisory Board

Retrieved on: 
Wednesday, October 4, 2023
Bacteriology, Laboratory, Mayo Clinic, University, Microbiology, Infection, DZD, ID, Science, Johns Hopkins University, Clinical professor, University of Virginia, University of Manitoba College of Medicine, Vaccine, Medical device

BOSTON, Oct. 4, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the addition of Patricia (Trish) Simner, Ph.D., M.Sc., to its clinical advisory board.

Key Points: 
  • BOSTON, Oct. 4, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the addition of Patricia (Trish) Simner, Ph.D., M.Sc., to its clinical advisory board.
  • "We are honored to have Dr. Simner join Day Zero Diagnostics' Clinical Advisory Board," said Jong Lee, CEO and co-founder of Day Zero Diagnostics.
  • "Day Zero Diagnostics' work in same day organism ID and genomic antimicrobial susceptibility prediction directly from specimen is an important area of innovation for the field of microbiology," said Dr. Simner.
  • Dr. Simner joins Dr. Robin Patel from Mayo Clinic and Dr. Amy Mathers from University of Virginia on the Microbiology Leadership subgroup of DZD's Clinical Advisory Board .

AM Best Affirms Credit Ratings of Compagnie Centrale de Réassurance

Retrieved on: 
Thursday, September 28, 2023
Professional Services, Insurance, Finance, CCR, Good, AM Best, ALL, Risk management, Compagnie Centrale de Réassurance, DZD, Credit, GWP, AM, News

AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” (Good) of Compagnie Centrale de Réassurance (CCR) (Algeria).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” (Good) of Compagnie Centrale de Réassurance (CCR) (Algeria).
  • The outlook of these Credit Ratings (ratings) is stable.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

BingX Expands Peer-to-Peer Trading Services to MENA Region and Turkey

Retrieved on: 
Monday, August 14, 2023
EGP, Partnership, KWD, SAR, Communication, QAR, JOD, DZD, TRY, Traction, AED, MAD, Ecosystem, Environment, PR, Cryptocurrency

BingX's expansion into the MENA region and Turkey comes at a time when P2P trading has gained substantial traction in the cryptocurrency industry.

Key Points: 
  • BingX's expansion into the MENA region and Turkey comes at a time when P2P trading has gained substantial traction in the cryptocurrency industry.
  • Building on its successful P2P trading services available in over 40 countries and regions with support for 300+ payment methods, BingX now extends its user-friendly and cost-effective trading experience to the MENA and Turkey market.
  • With the expansion of its P2P trading services, BingX is actively seeking merchants from the Middle East and Turkey and fostering a vibrant trading ecosystem.
  • To further engage with the MENA and Turkey community, users participating in P2P trading activities within the regions will be rewarded based on their trading volume.

BingX Expands Peer-to-Peer Trading Services to MENA Region and Turkey

Retrieved on: 
Monday, August 14, 2023
EGP, Partnership, KWD, SAR, Communication, QAR, JOD, DZD, TRY, Traction, AED, MAD, Ecosystem, Environment, PR, Cryptocurrency

BingX's expansion into the MENA region and Turkey comes at a time when P2P trading has gained substantial traction in the cryptocurrency industry.

Key Points: 
  • BingX's expansion into the MENA region and Turkey comes at a time when P2P trading has gained substantial traction in the cryptocurrency industry.
  • Building on its successful P2P trading services available in over 40 countries and regions with support for 300+ payment methods, BingX now extends its user-friendly and cost-effective trading experience to the MENA and Turkey market.
  • With the expansion of its P2P trading services, BingX is actively seeking merchants from the Middle East and Turkey and fostering a vibrant trading ecosystem.
  • To further engage with the MENA and Turkey community, users participating in P2P trading activities within the regions will be rewarded based on their trading volume.

AM Best Affirms Credit Ratings of Compagnie Centrale de Réassurance

Retrieved on: 
Thursday, October 6, 2022
Finance, Consulting, Banking, Professional Services, Insurance, Risk management, News, Insurance, AM Best, AM, Industry, CCR, DZD, GWP, Credit, Good, ALL

AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of bbb- (Good) of Compagnie Centrale de Rassurance (CCR) (Algeria).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of bbb- (Good) of Compagnie Centrale de Rassurance (CCR) (Algeria).
  • The outlook of these Credit Ratings (ratings) is stable.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • For information on the proper use of Bests Credit Ratings, Bests Performance Assessments, Bests Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Bests Ratings & Assessments .

Day Zero Diagnostics Welcomes Molecular Diagnostics Experts to its Advisory Board

Retrieved on: 
Wednesday, August 24, 2022
Zero, Hive, Massachusetts General Hospital, Machine learning, Subclinical infection, American Association for Clinical Chemistry, MassChallenge, Research, CEO, Gene, Eastern Virginia Medical School, Infection, Microbiology, Death, Associate, R, WGS, Culture, Molecular epidemiology, University, LinkedIn, Department, Diagnosis, Senior, Coronavirus Scientific Advisory Board (Turkey), Lancet, Hospital, CLIA, Harvard University, Molecular design software, Whole genome sequencing, Medical microbiology, Advisory board, DZD, Drug resistance, Twitter, LLC, Sepsis, Association, Review, Patient, Vaccine, Antibiotics, Medicine, Pathology

BOSTON, Aug. 24, 2022 /PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the addition of Dr. Amy Mathers and Rob Crisp to the company's Advisory Board.

Key Points: 
  • DZD is poised to revolutionize infectious disease diagnosis, reducing time to diagnosis of infections from days to hours
    "We are pleased to welcome Dr. Amy Mathers and Rob Crisp to the Day Zero Diagnostics Advisory Board.
  • "I'm impressed with Day Zero Diagnostics' sequencing-based rapid diagnostic technology that shortens the traditional wait time of a culture.
  • Crisp is currently Vice President, Research and Development at Molecular Designs, a team of doctors and scientists working to advance molecular diagnostics.
  • Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.